A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome
Clinical trial NCT03054896 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03054896
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-08
- Primary completion
- 2025-12-24
- Enrollment
- 69
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.